Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Authors:
Open Access
- 20 March 2024
- journal article
- research article
- Published by Springer Nature in BMC Women's Health
- Vol. 24 (1) , 1-13
Abstract
Background: Residual microcalcifications after neoadjuvant chemotherapy (NAC) are challenging for deciding extent of surgery and questionable for impact on prognosis. We investigated changes in the extent and patterns of microcalcifications before and after NAC and correlated them with pathologic response. We also compared prognosis of patients depending on presence of residual microcalcifications after NAC. Methods: A total of 323 patients with invasive breast carcinoma treated with neoadjuvant chemotherapy at Kangbuk Samsung Hospital and Samsung Medical center from March 2015 to September 2018 were included. Patients were divided into four groups according to pathologic response and residual microcalcifications. Non-pCRw/mic group was defined as breast non-pCR with residual microcalcifications. Non-pCRw/o mic group was breast non-pCR without residual microcalcifications. pCRw/mic group was breast pCR with residual microcalcifications. pCRw/o mic group was breast pCR without residual microcalcifications. The first aim of this study is to investigate changes in the extent and patterns of microcalcifications before and after NAC and to correlate them with pathologic response. The second aim is to evaluate oncologic outcomes of residual microcalcifications according to pathologic response after NAC. Results: There were no statistical differences in the extent, morphology, and distribution of microcalcifications according to pathologic response and subtype after NAC (all p > 0.05). With a median follow-up time of 71 months, compared to pCRw/o mic group, the hazard ratios (95% confidence intervals) for regional recurrence were 5.190 (1.160–23.190) in non-pCRw/mic group and 5.970 (1.840–19.380) in non-pCRw/o mic group. Compared to pCRw/o mic group, the hazard ratios (95% CI) for distant metastasis were 8.520 (2.130–34.090) in non-pCRw/mic group, 9.120 (2.850–29.200) in non-pCRw/o mic group. Compared to pCRw/o mic, the hazard ratio (95% CI) for distant metastasis in pCRw/mic group was 2.240 (0.230–21.500) without statistical significance (p = 0.486). Conclusions: Regardless of residual microcalcifications, patients who achieved pCR showed favorable long term outcome compared to non-pCR group.Keywords
This publication has 29 references indexed in Scilit:
- Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapyBreast Cancer Research and Treatment, 2022
- Preoperative evaluation of mammographic microcalcifications after neoadjuvant chemotherapy for breast cancerClinical Radiology, 2020
- Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort studyBreast Cancer Research and Treatment, 2016
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialThe Lancet Oncology, 2016
- Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatmentEuropean Journal of Surgical Oncology, 2016
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Microcalcifications in breast cancer: Lessons from physiological mineralizationBone, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survivalThe Breast, 2003
- Non‐palpable breast carcinomas: Correlation of mammographically detected malignant‐appearing microcalcifications and molecular prognostic factorsInternational Journal of Cancer, 2002